Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies  - Takeaways - MDSpire

Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies 

Eugene M. & Christine E. Lynn Cancer Institute has treated its first patient with tarlatamab, marking an important milestone in the expansion of advanced cancer therapies available to patients in Palm Beach County and the surrounding region.

  • May 7, 2026

  • 3 min

Share

  • 1

    Lynn Cancer Institute has treated its first patient with tarlatamab, expanding advanced cancer therapies in Palm Beach County.

  • 2

    Tarlatamab is significant for patients with extensive-stage small cell lung cancer, where treatment options are often limited.

  • 3

    Successful delivery of tarlatamab requires coordinated support from a multidisciplinary team across various medical specialties.

  • 4

    The availability of tarlatamab locally allows patients to access sophisticated treatment options without traveling far.

  • 5

    Lynn Cancer Institute plans to introduce additional T-cell engaging therapies, including bispecific antibodies, in the coming months.

Original Source(s)

Eugene M. & Christine E. Lynn Cancer Institute Treats First Patient with Tarlatamab, Expanding Advanced Therapeutic Options for Patients with Refractory Malignancies 

  • May 7, 2026

Related Content

2026 AACR Bladder Cancer Highlights

The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from AACR 2026.

  • June 17, 2026

  • 1 min
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101

A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.

  • July 1, 2026

  • 1 min
Mass Spec Roundup: Signals Recovered

This week’s stories span amino-metabolite imaging, site-specific HDX-MS, large-scale motif annotation, and proteomics missing-value recovery

  • July 15, 2026

  • 7 min